Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and linagliptin versus placebo in children and adolescents with type 2 diabetes
MOH_2018-08-15_002235Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Linagliptin, Empagliflozin and Placebo (3 arms). Primary endpoint: Efficacy versus placebo at 26 weeks. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
empagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2018-08-15_002235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-08-15_002235.